Applying the same dose and regimen as used in the SMARCA4mut xenograft studies, A947 did not result in tumor growth inhibition in SMARCA4wt Calu-6 xenografts despite achieving greater than 95% degradation of SMARCA2 protein (Fig. 4g, Supplementary Fig. 8a). This evidence concerns the gene SMARCA2 and neoplasm.